NFE2L2 and Parkinson disease: Therefore, in order to determine the therapeutic value of Nrf2-activating drugs for PD it is necessary to determine if HO-1, which will be up-regulated by Nrf2 activators through Nrf2-depedent transcription, has a neuroprotective or neurotoxic role.